Fiduciary Group’s Colgate-Palmolive CL Stock Holding History

Fiduciary Group’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$824K	Sell	9,671 -337	-3%	-$30K	0.07%	173
2025 Q4	$791K	Sell	10,008 -2,870	-22%	-$225K	0.07%	172
2025 Q3	$1.03M	Sell	12,878 -345	-3%	-$29.4K	0.09%	157
2025 Q2	$1.2M	Sell	13,223 -30	-0.2%	-$2.74K	0.11%	143
2025 Q1	$1.24M	Buy	13,253 +1,210	+10%	+$108K	0.12%	137
2024 Q4	$1.09M	Buy	12,043 +3,345	+38%	+$319K	0.11%	142
2024 Q3	$903K	Sell	8,698 -113	-1%	-$11.5K	0.09%	153
2024 Q2	$855K	Sell	8,811 -140	-2%	-$12.9K	0.09%	157
2024 Q1	$806K	Buy	8,951 +1,300	+17%	+$110K	0.09%	152
2023 Q4	$610K	Buy	7,651 +530	+7%	+$39.9K	0.07%	158
2023 Q3	$506K	Buy	7,121 +39	+0.6%	+$2.92K	0.06%	164
2023 Q2	$546K	Sell	7,082 -331	-4%	-$25.6K	0.07%	155
2023 Q1	$557K	Buy	7,413 +77	+1%	+$5.73K	0.07%	149
2022 Q4	$578K	Buy	7,336 +146	+2%	+$10.9K	0.08%	146
2022 Q3	$539K	Buy	7,190 +410	+6%	+$32.1K	0.07%	151
2022 Q2	$539K	Sell	6,780 -61	-0.9%	-$4.77K	0.07%	150
2022 Q1	$525K	Hold	6,841	–	–	0.07%	147
2021 Q4	$584K	Sell	6,841 -175	-2%	-$13.7K	0.07%	150
2021 Q3	$534K	Hold	7,016	–	–	0.06%	153
2021 Q2	$549K	Sell	7,016 -360	-5%	-$29.4K	0.06%	150
2021 Q1	$595K	Sell	7,376 -400	-5%	-$31.4K	0.07%	142
2020 Q4	$610K	Sell	7,776 -200	-3%	-$16.5K	0.08%	139
2020 Q3	$615K	Sell	7,976 -157	-2%	-$12K	0.09%	128
2020 Q2	$596K	Sell	8,133 -245	-3%	-$17.4K	0.1%	124
2020 Q1	$556K	Sell	8,378 -25	-0.3%	-$1.76K	0.11%	115
2019 Q4	$578K	Hold	8,403	–	–	0.09%	126
2019 Q3	$618K	Sell	8,403 -34	-0.4%	-$2.47K	0.11%	114
2019 Q2	$605K	Buy	8,437 +34	+0.4%	+$2.41K	0.11%	118
2019 Q1	$576K	Buy	8,403 +378	+5%	+$24.4K	0.11%	115
2018 Q4	$478K	Hold	8,025	–	–	0.1%	118
2018 Q3	$537K	Sell	8,025 -400	-5%	-$26.6K	0.11%	122
2018 Q2	$546K	Hold	8,425	–	–	0.12%	116
2018 Q1	$604K	Buy	8,425 +400	+5%	+$28.8K	0.13%	109
2017 Q4	$605K	Hold	8,025	–	–	0.13%	111
2017 Q3	$585K	Hold	8,025	–	–	0.13%	112
2017 Q2	$595K	Hold	8,025	–	–	0.14%	112
2017 Q1	$587K	Hold	8,025	–	–	0.14%	117
2016 Q4	$525K	Hold	8,025	–	–	0.14%	119
2016 Q3	$595K	Sell	8,025 -40	-0.5%	-$2.96K	0.16%	114
2016 Q2	$590K	Sell	8,065 -195	-2%	-$13.9K	0.16%	111
2016 Q1	$584K	Buy	8,260 +550	+7%	+$36.6K	0.17%	113
2015 Q4	$514K	Buy	7,710 +100	+1%	+$6.65K	0.15%	118
2015 Q3	$483K	Hold	7,610	–	–	0.16%	132
2015 Q2	$498K	Buy	+7,610	New	+$516K	0.16%	137

Other funds holding CL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Fiduciary Group's CL Position: Q1 2026 in Review

Fiduciary Group reduced its Colgate-Palmolive (CL) stake by 3.4% in Q1 2026, selling an estimated $30K and leaving 9,671 shares worth $824K. The position accounts for 0.07% of the portfolio, ranked #173.

Fiduciary Group first reported a position in CL in Q2 2015 and has held it in 44 quarters since. The position peaked at $1.24M in Q1 2025. 1,946 funds tracked by Wall St. Rank hold CL as of Q1 2026.

Fiduciary Group held 9,671 shares of Colgate-Palmolive worth $824K as of Q1 2026.
Fiduciary Group sold 337 Colgate-Palmolive shares in Q1 2026, an estimated $30K.
Colgate-Palmolive made up 0.07% of Fiduciary Group's portfolio in Q1 2026, its #173 holding.
Fiduciary Group first reported a position in Colgate-Palmolive in Q2 2015 and has held it in 44 quarters since.
Fiduciary Group's Colgate-Palmolive position peaked at $1.24M in Q1 2025.
1,946 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2026.

Based on Fiduciary Group's 13F filing for Q1 2026, filed 11 May 2026.